How dengue fever affects people with sickle cell disease
Studies how dengue virus infection affects people with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Key facts
- Where
- Pointe-à-Pitre, GuadeloupeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people with sickle cell disease (SS or SC type) followed at the sickle cell center of Guadeloupe, and healthy volunteers with normal hemoglobin (AA) as a control group.
- Age
- Older than 6 years and younger than 25 years.
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of the SS or SC type, confirmed by electrophoresis or HPLC. Clinically stable at inclusion, with no complication in the last month.
- Earlier treatment
- No blood transfusion in the last three months.
- Biomarker or test result
- Hemoglobin type SS or SC for patients; hemoglobin AA for the control group.
Main reasons for not taking part
- Complication of the disease in the last month
- Blood transfusion in the last three months
- Not followed for sickle cell disease at the sickle cell center of Guadeloupe (for patients)
- Not affiliated to national social security
- No written informed consent from the person or the legal representative
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 25 years old?
Source: NCT07000747, who can take part
Where in Guadeloupe
- CHU de la GuadeloupePointe-à-Pitre, GuadeloupeContact: Maryse etienne julan, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Trial code
- NCT07000747
- Record updated
- 3 June 2025
- Original description
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date.Read full original descriptionShow less
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date.
The aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.
Inclusion: patients with SS or SC SCD or controls with hemoglobin AA; diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies; patients older than 6 years and younger than 25 at inclusion; clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months); patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre); patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki; patients affiliated to national social security; the control group (AA subjects) will be recruited among volunteers recruited by posters.
Exclusion: patients with SS or SC SCD or controls with hemoglobin AA; diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies; patients older than 6 years and younger than 25 at inclusion; clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months); patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre); patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki; patients affiliated to national social security; the control group (AA subjects) will be recruited among volunteers recruited by posters.